ABSTRACT
Chronic lung disease is now recognized as an increasingly important risk factor for developing pulmonary aspergillosis. The development of specific aspergillusassociated syndromes depends on host immunity and underlying lung disease. In the setting of asthma, hypersensitivity to Aspergillus can lead to allergic bronchopulmonary aspergillosis (ABPA) or severe asthma with fungal sensitization (SAFS). Cystic fibrosis (CF) also has a recognized preponderance for ABPA. Chronic use of high-dose systemic or inhaled corticosteroids coupled with recurrent antibiotic use for exacerbations prevalent in chronic obstructive pulmonary disease (COPD) predisposes to chronic pulmonary aspergillosis with high morbidity. Prior pulmonary tuberculosis is a risk factor for chronic pulmonary aspergillosis, a syndrome with a wide range of presentations including a simple aspergilloma, chronic cavities, chronic necrosis or chronic fibrosis.
Accumulating evidence suggests that the presence of or colonization by Aspergillus in the setting of chronic lung disease can worsen its clinical course and outcomes even in the absence of overt pulmonary aspergillosis. We propose that understanding the complex interplay between host and fungi in the context of the pulmonary mycobiome may provide key insights into the pathogenesis of Aspergillus-associated pulmonary syndromes in the setting of chronic lung disease, and provide novel therapeutic approaches to improve its identification and management.
INTRODUCTION
A historical case series published in 1968 surveyed 107 consecutive patients attending hospital with various chronic chest diseases including asthma, bronchiectasis, emphysema, chronic bronchitis, and cavitatory lung disease. It found that precipitins to Aspergillus spp. were common, with approximately 10% of patients having confirmed pulmonary aspergillosis (1) . Today, over four decades later chronic lung disease is clearly becoming an increasingly important predisposing factor for the development of pulmonary aspergillosis. This is in addition to established risks from malignancies and solid organ transplantation. There clearly is a growing number affected with structural lung disease or dysfunctional immune states. These are associated with either the chronic inflammatory respiratory disease itself or as a consequence of their management conferring higher risks for pulmonary aspergillosis. In fact, Aspergillus has now overtaken Candida as the chief cause of fungal disease (2).
Here we review the specific pulmonary aspergillosis syndromes occurring in asthma, COPD, bronchiectasis, CF and pulmonary tuberculosis. We also present evidence of the ability of Aspergillus to influence the clinical course and outcomes of patients with chronic respiratory disease. We propose that understanding and recognizing the role of the pulmonary mycobiome is crucial for developing new therapeutic strategies to counter the growing threat of Aspergillus in chronic respiratory disease states.
ASPERGILLUS SPP. AND PULMONARY ASPERGILLOSIS SYNDROMES
Aspergillus species are ubiquitous molds commonly found in soil and decaying organic matter. Also widely disseminated in the atmosphere as spores, each of us regularly inhales thousands of spores daily that are able to access even the most distal airways owing to their size and durability. There are over 180 species of Aspergillus described with A. fumigatus, A. flavus and A. niger representing the most common implicated in human disease.
Aspergillus spp. cause a wide spectrum of pulmonary disease in the human host, which in turn depends on the state of the underlying host immune system, virulence of the infecting organism and degree of chronic lung disease (3, 4) . Aspergillus virulence is multifactorial and under polygenetic control. Strategies used by the fungi are multifaceted and include fungal structure, capacity for growth, adaptation to stressful conditions, the ability to damage host cells and evade immune-recognition, all features that can be exploited as either diagnostic or therapeutic targets (5) (6) (7) (8) (9) . In individuals with normal immunity and no chronic lung disease, inhaled conidia are usually cleared by anatomical barriers, functional macrophages and neutrophils (7, 10) , and as such do not lead to clinically significant sequelae. However, in immunocompetent or mildly immunosuppressed individuals where there is underlying structural lung disease such as cavitation, disease may manifest as a simple aspergilloma or fungal ball sequestered within the cavity. This is usually without evidence of tissue invasion. In patients with ongoing mild immunosuppression for instance from chronic corticosteroid usage; a more indolent focal form of disease known as chronic pulmonary aspergillosis can occur. This can be challenging to identify particularly in the setting of severe and destructive chronic respiratory disease observed in post tuberculosis states or severe bronchiectasis. In severely immunocompromised patients, such as those with hematological cancers or organ/stem cell transplant recipients, Aspergillus may cause invasive pulmonary aspergillosis, with germination of the conidia into hyphae that subsequently invade into the lung parenchyma and associated vasculature resulting in systemic spread. This carries very high mortality and remains difficult to diagnose especially in its earliest stage.
Paradoxically, immune hypersensitivity to Aspergillus can also lead to pathology such as ABPA, which is characterized by uncontrolled airway inflammation and bronchospasm, which if left unrecognized and treated will lead to bronchiectasis and pulmonary fibrosis placing patients at further risk of other Aspergillus-associated syndromes.
ASPERGILLUS SPP. AND CHRONIC RESPIRATORY DISEASE
The manifestations of Aspergillus-associated disease differs between the various chronic respiratory disease states however certain forms may be predominant in particular disease. It is however important to note that any patient at any time may exhibit any of the described Aspergillus-associated syndromes that is largely dictated by the underlying state of host immunity (Figure 1 ). Therefore, Aspergillus-associated disease exists along a spectrum of structural and functional pulmonary derangements, a single patient therefore can evolve over time from one Aspergillus-associated disease to another, or simultaneously exhibit several diseases making the identification of such clinical states particularly in the context of chronic lung disease diagnostically challenging. The host's underlying immune state, while dictating the form of Aspergillus-associated disease is often additionally influenced by the specific milieu of immune suppression or hypersensitivity, structural lung or airway changes, and sequelae of treatment for the underlying chronic respiratory disease. Further, in the absence of overt pulmonary aspergillosis, even simple colonization or sensitization to Aspergillus can worsen the underlying respiratory disease particularly in terms of pulmonary outcomes such as lung function and exacerbations.
Aspergillus and asthma
Asthma is a chronic inflammatory airways disease with variable airflow obstruction. There is an association between Aspergillus and asthma development and, Aspergillus can also influence the clinical asthma phenotype. A large case control study conducted in Finland found that exposure to Aspergillus and the presence of IgE antibodies to Aspergillus increases the risk of adult-onset asthma (11) . In addition, Aspergillus has been implicated in the development of unique asthma phenotypes (12) .
One clear example of the link between asthma and Aspergillus spp. is ABPA, a recognized phenotype of asthma induced by a type 1 IgE mediated hypersensitivity to Aspergillus, most commonly but not exclusive to A. fumigatus (13) .
Currently, the diagnostic criteria for ABPA includes the presence of asthma, skin prick test sensitivity to Aspergillus, total IgE > 416 IU/ml, increased Aspergillus-specific IgE or IgG and radiographic infiltrates (14) . Additional criteria include peripheral blood eosinophilia, Aspergillus serum precipitating antibodies, central bronchiectasis or Aspergillus-containing mucous plugs ( Figure 2 ). ABPA tends to present as severe refractory asthma, and its treatment requires prolonged systemic steroids, with potential utility of antifungal agents (15) . Itraconazole has been shown in several studies, including randomized control trials, to lead to improvements in disease outcomes including serology (decreased Aspergillus fumigatus IgE and IgG levels), improved lung function, reduction in steroid dose and exacerbations (16) . Voriconazole and posaconazole have also been demonstrated in retrospective studies to be effective alternate treatments for ABPA (17) . Other potential alternative therapeutic approaches have also been examined for instance use of the monoclonal antibody against IgE (Omalizumab) and nebulized amphotericin B. Both have illustrated efficacy in ABPA in small proof-of-concept studies, but the need for a large, prospective randomized controlled trial to confirm efficacy persists (18, 19) . Importantly, treatment of ABPA with long-term prolonged oral corticosteroids places patients at risk of immunosuppression and thus chronic aspergillosis syndromes, a real but unintended side effect of optimal ABPA therapy hence the importance of considering steroid sparing approaches.
In addition to ABPA, Aspergillus can have other wide-ranging more subtle effects on the asthma phenotype. For example, some asthma patients have evidence of Aspergillus hypersensitivity but do not meet diagnostic criteria for ABPA. They have been described as Severe Asthma with Fungal Sensitization (SAFS) (20) . In multiple studies, the prevalence of sensitization to Aspergillus, either assessed by skin prick testing or specific IgEs is been estimated to be as high as 28%-45% (21, 22) . Sensitivity to Aspergillus even in the absence of clinical ABPA is associated with poorer asthma outcomes including severe exacerbations requiring hospitalization (22) , intensive care unit admissions (23) , lower FEV 1 (24) and fixed airway obstruction (25) . 
Aspergillus and chronic obstructive pulmonary disease
COPD is a chronic inflammatory lung disease characterized by chronic progressive irreversible airflow obstruction, usually but not exclusively driven by smoking. Aspergillus is commonly recovered from the respiratory specimens of COPD patients, for example, a prospective study looking at patients presenting to hospital with an acute exacerbation of COPD found that the prevalence of Aspergillus isolation from sputum was 16.6% on admission and 14.1% at one year follow up. This was also associated with more frequent exacerbations in the preceding year (32) . Another multicenter prospective study of patients admitted to the intensive care unit found that COPD and steroids were associated with Aspergillus isolation from tracheal aspirates with odds ratios of 2.9 and 4.5 respectively (33). Between 8-15% of COPD patients remarkably show evidence of hypersensitivity to Aspergillus (34, 35) , which in turn is associated with worse pulmonary function and potentially asthma-COPD overlap syndrome (ACOS) (36) .
There is an increasing recognition that Aspergillus may not be a mere colonizer of the COPD airway, but in fact possess significant potential to evolve into invasive pulmonary aspergillosis (IPA) (37) . This emerging and serious infection in patients with COPD is a particular risk in patients receiving high-dose systemic corticosteroids (38, 39) or recurrent courses of antibiotics (40), or even high-dose inhaled corticosteroids (41) 
Aspergillus and bronchiectasis
Bronchiectasis is characterized by a permanent irreversible dilatation of the airways, with accompanying inflammation, chronic bacterial infection and destruction of the bronchial walls. In about 10% of patients with "idiopathic" bronchiectasis, ABPA can be identified as the causative factor (47) Rates of Aspergillus colonization in CF range from 15-50% with up to 10% having ABPA that remains difficult to identify because of overlapping clinical, microbiological, radiological and immunological effects to that seen in a bacterial exacerbation (8) .
Importantly, no correlation exists between isolation of airway Aspergillus and occurrence of CF-ABPA that adds a further level of complexity to differentiate the colonized from diseased state within the CF airway (6, 53) . In the context of Aspergillus colonization in CF, our group has performed a significant body of work and are now extending this to non-CF settings (7, (53) (54) (55) . Immunosuppressive roles of gliotoxin include the inhibition of phagocytosis, T-cell proliferation, mast cell activation and cytotoxicity. Additionally, it inhibits superoxide production and reduces epithelial ciliary movement leading to dysfunction. We are currently assessing its precise role for both diagnostic and therapeutic value in the context of both CF and non-CF bronchiectasis (7) (8) (9) . positive sputum cultures in the preceding 12 months) in CF was negative, with no difference in outcomes of lung function, exacerbation rates, and quality of life (70) . This was in contrast to observational work performed by our group where clinical and radiological benefits were noted (56) . Importantly, the work by Aaron et al (70) was significantly limited by lack of power, sub-therapeutic levels of oral itraconazole achieved in more than half of the patients assessed and failed to assess any endpoint beyond FEV 1 . As a consequence, the precise role for Aspergillus spp. in the context of bronchiectasis particularly in modulating its clinical course and progression requires further and more detailed study beyond measures such as FEV 1 alone.
Aspergillus and pulmonary tuberculosis
Association between Aspergillus and pulmonary tuberculosis (PTB) has been recognized for several decades. In a British series from the 1960s, 25% of all patients with residual cavities >2.5cm after PTB treatment had detectable Aspergillus precipitins in blood and both precipitins and radiological features of an aspergilloma were detected in 14% and 22% respectively at 1 and 4 years (71) . In a more recent study of PTB patients in Iran, using direct microscopic examination of sputum, fungal culture and radiographic examination, 2.4% of patients met criteria for an aspergilloma and 11.3% of patients for chronic cavitatory pulmonary aspergillosis (72) . Prior PTB remains the strongest risk factor for CPA (73) . It is estimated that at least 1.2 million people around the world have CPA as a sequel to PTB (74) . In fact, many cases of TB-related CPA are undiagnosed, as CPA regularly masquerades as smear-negative TB with an absence of pyrexia (75) .
CPA occurs along a disease spectrum. A simple aspergilloma is a fungal ball occurring in a single pulmonary cavity that remains stable over a period of time ( Figure   4 ). In contrast, chronic cavitatory pulmonary aspergillosis begins as ill- 
THE MYCOBIOME AND TRANSLATING SCIENCE TO TREATMENT
The total lung microbiome is defined as the microbial communities present in the airway and comprises bacterial, fungal and viral organisms. In recent years it has become evident that the microbiome with which each individual is colonized has wide-ranging effects on human phenotype in both health and disease. It has roles in immune-regulation, metabolism and other physiological processes that influence physiological homeostasis.
Although most research has mainly focused on bacterial contributions to the human microbiome, fungi remain an important and clearly understudied contributor to airway health and disease. Consequently, the term "mycobiome" has been coined to refer to the fungal component of the described human microbiome (83) .
Changes or dysbiosis within the lung micro-or mycobiome composition may potentially provide insight into how Aspergillus is able to thrive within chronically- 
CONCLUSION
In summary, Aspergillus is emerging as a common link across various chronic lung disease states, such as asthma, COPD, bronchiectasis, cystic fibrosis and pulmonary tuberculosis. Different chronic lung diseases have preponderance for different pulmonary aspergillosis syndromes depending on the underlying state of the host immune system.
Even in the absence of clinically overt pulmonary aspergillosis, the presence of Aspergillus in the airways of patients with chronic lung disease can worsen clinical course and disease outcomes. Understanding lung micro-and mycobiome interaction may provide insights into the pathogenesis of Aspergillus-related diseases in the context of chronic lung disease, and provide us novel diagnostic or therapeutic approaches.
